Skip to main content

Novo Nordisk's parent to buy Catalent for $16.5B to boost Wegovy supply

By Reuters  
   February 07, 2024

Novo Nordisk parent company says its buying Catalent, a key manufacturing subcontractor of Wegovy, for $16.5 billion.

Full story


Get the latest on healthcare leadership in your inbox.